Tag: clinical trials

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence

November 15, 2025November 15, 2025 digi

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Introduction to Inspection Readiness and ICH E6(R3) The evolving landscape of clinical trials necessitates a framework that enhances compliance and ensures data integrity. The International Council for Harmonisation (ICH) E6(R3) guidelines…

ICH E6(R3) Principles & Proportionality

Integrating QMS, GCP and PV Requirements Across the Development Portfolio

November 15, 2025November 15, 2025 digi

Integrating QMS, GCP and PV Requirements Across the Development Portfolio Integrating QMS, GCP and PV Requirements Across the Development Portfolio The clinical trial landscape is increasingly complex due to the growing regulatory requirements and the high stakes involved in drug development. An effective Quality Management System (QMS) that integrates Good Clinical Practice (GCP) and Pharmacovigilance…

Quality Management System (QMS) Design

Using Investigator Meetings to Clarify Complex Endpoints and Assessments

November 15, 2025November 15, 2025 digi

Using Investigator Meetings to Clarify Complex Endpoints and Assessments Using Investigator Meetings to Clarify Complex Endpoints and Assessments Investigator meetings are critical components in the development of successful clinical trials, particularly for complex studies involving nuanced endpoints and assessments. These meetings serve as a platform for site management organizations, clinical research teams, and investigators to…

Investigator Meeting & Site Initiation Visit

Engagement Tactics to Turn Investigators Into Study Champions

November 15, 2025November 15, 2025 digi

Engagement Tactics to Turn Investigators Into Study Champions Engagement Tactics to Turn Investigators Into Study Champions In the ever-evolving landscape of clinical research, the role of investigators is paramount. Not only do they conduct the trials, but they also influence patient recruitment, retention, and overall study success. Proper engagement strategies can turn an ordinary investigator…

Investigator Meeting & Site Initiation Visit

Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio

November 15, 2025November 15, 2025 digi

Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio The successful implementation of ICH E6(R3) guidelines requires a comprehensive understanding of roles, responsibilities, and compliance expectations across different functional areas within pharmaceutical and clinical research organizations. In this article, we will provide a step-by-step…

ICH E6(R3) Principles & Proportionality

Risk Assessment and Risk Control Requirements Under Updated GCP

November 15, 2025November 15, 2025 digi

Risk Assessment and Risk Control Requirements Under Updated GCP Understanding Risk Assessment and Risk Control Requirements Under Updated GCP Introduction to ICH E6(R3) and Its Impact on Clinical Trials The International Council for Harmonisation (ICH) has been instrumental in setting the standards for Good Clinical Practice (GCP) globally. The release of ICH E6(R3) introduces significant…

ICH E6(R3) Principles & Proportionality

Translating Corporate Quality Policies Into Study-Level QMS Controls

November 15, 2025November 15, 2025 digi

Translating Corporate Quality Policies Into Study-Level QMS Controls The successful execution of clinical trials relies on the rigorous application of a Quality Management System (QMS) that adheres to corporate quality policies while addressing study-specific requirements. This comprehensive guide outlines a step-by-step tutorial for clinical operations, regulatory affairs, and medical affairs professionals in the US, UK,…

Quality Management System (QMS) Design

Standardized SIV Checklists for Drug, Device and Combination Product Trials

November 15, 2025November 15, 2025 digi

Standardized SIV Checklists for Drug, Device and Combination Product Trials Standardized SIV Checklists for Drug, Device and Combination Product Trials The initiation of clinical trials is a critical activity that requires meticulous planning and execution. Site Initiation Visits (SIVs) represent a vital stage in the clinical trial lifecycle, ensuring that clinical sites are prepared to…

Investigator Meeting & Site Initiation Visit

Proportionate GCP Oversight for Low-Intervention and Pragmatic Clinical Trials

November 15, 2025November 15, 2025 digi

Proportionate GCP Oversight for Low-Intervention and Pragmatic Clinical Trials Clinical trials serve as the cornerstone of medical research, enabling the testing of new treatments and medical interventions to improve patient outcomes. However, the extent of oversight and regulation applied to clinical trials can vary significantly based on the nature of the trial itself. This article…

ICH E6(R3) Principles & Proportionality

Embedding ICH E6(R3) Into SOPs, Templates and Study Governance

November 15, 2025November 15, 2025 digi

Embedding ICH E6(R3) Into SOPs, Templates and Study Governance The International Council for Harmonisation (ICH) E6(R3) provides comprehensive guidance intended to strengthen the quality of clinical trials globally. This article outlines a structured approach for clinical operations, regulatory affairs, and medical affairs professionals to effectively embed ICH E6(R3) principles into Standard Operating Procedures (SOPs), templates,…

ICH E6(R3) Principles & Proportionality